Precision Biosciences Inc (DTIL) CFO details stock and major RSU grants
Rhea-AI Filing Summary
Naresh Haresh Tanna, Chief Financial Officer of Precision Biosciences Inc, reports direct ownership of 25,575 shares of common stock. Reported equity awards include RSU grants of 16,683, 33,317, 45,000 and 179,340 units, each vesting in three substantially equal annual installments beginning on January 20, 2025, January 27, 2025, February 17, 2026 and February 19, 2027, respectively, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Tanna Naresh Haresh
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Restricted Stock Units F2, F1 | -- | -- | -- |
| holding | Restricted Stock Units F2, F3 | -- | -- | -- |
| holding | Restricted Stock Units F2, F4 | -- | -- | -- |
| holding | Restricted Stock Units F2, F5 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 226,006 shares (Direct);
Common Stock — 25,575 shares (Direct)
Footnotes (5)
- F1. On April 18, 2024, the reporting person was granted 16,683 restricted stock units ("RSUs"), which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
- F2. The Reporting Person was granted RSUs, which each represents a contingent right to receive one share of the Company's Common Stock.
- F3. On August 22, 2024, the reporting person was granted 33,317 RSUs, which vest in three substantially equal annual installments beginning on January 27, 2025, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
- F4. On June 2, 2025, the reporting person was granted 45,000 RSUs, which vest in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
- F5. On June 1, 2026, the reporting person was granted 179,340 RSUs, which vest in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
Key Figures
Direct common shares held: 25,575 shares
RSU grant on April 18, 2024: 16,683 RSUs
RSU grant on August 22, 2024: 33,317 RSUs
+2 more
5 metrics
Direct common shares held
25,575 shares
Directly owned Precision Biosciences common stock as of 2026-08-01
RSU grant on April 18, 2024
16,683 RSUs
Vests in three substantially equal annual installments beginning January 20, 2025
RSU grant on August 22, 2024
33,317 RSUs
Vests in three substantially equal annual installments beginning January 27, 2025
RSU grant on June 2, 2025
45,000 RSUs
Vests in three substantially equal annual installments beginning February 17, 2026
RSU grant on June 1, 2026
179,340 RSUs
Vests in three substantially equal annual installments beginning February 19, 2027
Key Terms
Restricted Stock Units, contingent right, annual installments, continued service
4 terms
Restricted Stock Units financial
"the reporting person was granted 16,683 restricted stock units ("RSUs")"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"each represents a contingent right to receive one share"
annual installments financial
"vest in three substantially equal annual installments"
continued service financial
"subject to the Reporting Person's continued service to the Company"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity does Precision Biosciences (DTIL) CFO Naresh Tanna report owning?
Naresh Tanna reports direct ownership of 25,575 shares of Precision Biosciences common stock, plus several restricted stock unit (RSU) grants that provide contingent rights to receive additional shares as they vest over time.
What RSU grants has Precision Biosciences (DTIL) CFO received and in what amounts?
Reported RSU grants to the CFO total 16,683, 33,317, 45,000 and 179,340 units. Each RSU represents a contingent right to receive one share of Precision Biosciences common stock, subject to vesting and continued service conditions.
When do the RSUs reported for Precision Biosciences (DTIL) CFO begin vesting?
The RSU grants begin vesting on January 20, 2025, January 27, 2025, February 17, 2026 and February 19, 2027. Each grant vests in three substantially equal annual installments, contingent on continued service to Precision Biosciences.
How are the RSUs for Precision Biosciences (DTIL) CFO structured?
Each RSU reported for the CFO represents a contingent right to receive one share of Precision Biosciences common stock. The units vest in three substantially equal annual installments, and vesting requires the executive’s continued service through each vesting date.
What is the largest RSU grant reported for Precision Biosciences (DTIL) CFO Naresh Tanna?
The largest reported RSU grant to the CFO is 179,340 units, granted on June 1, 2026. These RSUs vest in three substantially equal annual installments beginning on February 19, 2027, subject to the CFO’s continued service with the company.